Joint sessions

Monday 05 May

15:45-17:15

ASPC/EAS Joint session - Triglycerides: From Pathophysiology to Clinical Practice

Hypertriglyceridemia and Atherosclerosis: Beyond LDL-C
Michael Shapiro, USA
Triglycerides, Remnant Cholesterol, and ASCVD Risk: Practical Guidance for Clinicians
Martha Gulati, USA
The Genetics of Hypertriglyceridemia: Insights into Pathophysiology and Risk
Anne Tybjærg-Hansen, Denmark
Novel Approaches to Lowering Triglycerides: Current and Future Therapies
Marcello Arca, Italy

Tuesday 06 May

11:00-12:30

ESC/EAS Joint session: New Horizons in the Understanding of the Inflammatory Nature of Atherosclerosis

Role of incretins in control of vascular disease and function
Elena Osto, Austria
New Immune Players in Atherosclerosis - Implications for Diagnosis and Therapy
Claudia Monaco, UK
Autoimmune Diseases and ASCVD
Christoph Binder, Austria
Residual Cardiovascular Risk
Alberto Zambon, Italy

Tuesday 06 May

15:45-17:15

IAS/EAS Joint session: FH – Current status worldwide and how can implementation science help us improve

FH and implementation science (including IAS FH Guidance document)
Gerald Watts, Australia
Update from HICC registry
Marina Cuchel, USA
Update from FHSC
Antonio Vallejo-Vaz, Spain
Family planning in FH: practical guidance
Kirsten Holven, Norway

Monday 05 May

11:00-12:30

NLA/EAS joint session: Early, Sustained, and Comprehensive Control of Lipids and Health: From Therapies to Models of Care

LDL-C Reduction
Kausik Ray, UK
Remnant Cholesterol and Triglyceride-Rich Lipoproteins
Borge Nordestgaard, Denmark
Lp(a) Management
Christie Ballantyne, USA
Systems Approaches to Improving Lipid Management
Kaye Eileen Willard, USA